On May 6, 2021, Trevena announced that TRV027, the Companyﾒs novel AT1 receptor selective agonist, had been selected for an NIH ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial in COVID-19 patients. The objective of ACTIV-4d RAAS was to evaluate treatments targeting the RAAS and to determine whether modulation of the RAAS is an effective strategy for preventing progression to critical illness, multiorgan failure, or mortality in hospitalized COVID-19 patients.